Testing a new drug combo for early HER2+ breast cancer before surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early or locally advanced breast cancer that is HER2-positive (a protein that helps cancer grow).
- Your tumor is larger than 2 cm or has spread to nearby lymph nodes.
- You are between 18 and 70 years old.
- You are generally well enough to carry out daily activities (ECOG score 0-1) and have a life expectancy over 6 months.
- You have not had any chemotherapy, hormone therapy, or anti-HER2 treatment for breast cancer in the last 3 years.
- You do not have active autoimmune disease, uncontrolled heart conditions, or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial tests a new combination of two targeted drugs (Trastuzumab Rezetecan and Pertuzumab) given before surgery for HER2-positive breast cancer. The goal is to see if this approach shrinks tumors more effectively.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.